A detailed history of Jb Capital LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Jb Capital LLC holds 5,694 shares of BMY stock, worth $330,252. This represents 0.02% of its overall portfolio holdings.

Number of Shares
5,694
Previous 5,700 0.11%
Holding current value
$330,252
Previous $236,000 24.58%
% of portfolio
0.02%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$39.66 - $51.75 $237 - $310
-6 Reduced 0.11%
5,694 $294,000
Q2 2024

Jul 24, 2024

SELL
$40.25 - $52.99 $1,610 - $2,119
-40 Reduced 0.7%
5,700 $236,000
Q1 2024

Apr 30, 2024

SELL
$47.98 - $54.4 $55,896 - $63,376
-1,165 Reduced 16.87%
5,740 $311,000
Q4 2023

Jan 22, 2024

BUY
$48.48 - $57.85 $6,787 - $8,099
140 Added 2.07%
6,905 $354,000
Q3 2023

Oct 25, 2023

SELL
$57.89 - $64.73 $6,657 - $7,443
-115 Reduced 1.67%
6,765 $392,000
Q2 2023

Jul 25, 2023

SELL
$63.71 - $70.74 $4,905 - $5,446
-77 Reduced 1.11%
6,880 $439,000
Q1 2023

Apr 25, 2023

BUY
$65.71 - $74.53 $28,518 - $32,346
434 Added 6.65%
6,957 $482,000
Q4 2022

Jan 23, 2023

BUY
$68.48 - $81.09 $1,985 - $2,351
29 Added 0.45%
6,523 $0
Q3 2022

Oct 14, 2022

SELL
$0.13 - $76.84 $33 - $19,824
-258 Reduced 3.82%
6,494 $462,000
Q2 2022

Jul 28, 2022

BUY
$72.62 - $79.98 $1,960 - $2,159
27 Added 0.4%
6,752 $520,000
Q1 2022

Apr 19, 2022

BUY
$61.48 - $73.72 $21,579 - $25,875
351 Added 5.51%
6,725 $492,000
Q4 2021

Feb 02, 2022

SELL
$53.63 - $62.52 $16,196 - $18,881
-302 Reduced 4.52%
6,374 $397,000
Q3 2021

Dec 08, 2021

BUY
$59.17 - $69.31 $395,018 - $462,713
6,676 New
6,676 $395,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Jb Capital LLC Portfolio

Follow Jb Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jb Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jb Capital LLC with notifications on news.